A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(32 sites)

United States

UCLA Medical Center, Los Angeles, California

Hoag Memorial Hospital Presbyterian, Newport Beach, California

Mayo Clinic - Rochester, Rochester, Minnesota

Uni Of TX MD Anderson Cancer Cntr, Houston, Texas

University Of Wisconsin, Madison, Wisconsin

Australia

Novartis Investigative Site, Darlinghurst, New South Wales

Novartis Investigative Site, Malvern, Victoria

Canada

Novartis Investigative Site, Toronto, Ontario

Novartis Investigative Site, Montreal, Quebec

China

Novartis Investigative Site, Guangzhou

Novartis Investigative Site, Tianjin

France

Novartis Investigative Site, Bordeaux

Novartis Investigative Site, Grenoble

Novartis Investigative Site, Saint-Herblain

Novartis Investigative Site, Strasbourg

Novartis Investigative Site, Villejuif

Germany

Novartis Investigative Site, Erlangen

Novartis Investigative Site, Essen

Novartis Investigative Site, Tübingen

Italy

Novartis Investigative Site, Meldola, FC

Novartis Investigative Site, Reggio Emilia, RE

Netherlands

Novartis Investigative Site, Delft, South Holland

Portugal

Novartis Investigative Site, Porto

Singapore

Novartis Investigative Site, Singapore

South Korea

Novartis Investigative Site, Seoul

Spain

Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona

Novartis Investigative Site, Barcelona

Novartis Investigative Site, Madrid

Novartis Investigative Site, Seville

United Kingdom

Novartis Investigative Site, London

Novartis Investigative Site, Sheffield